Faron Pharmaceuticals Oy (FARN) Price & Analysis

Compare

35 Followers

FARN Stock Chart & Stats

Day’s Range― - ―

52-Week Range140.00p - 270.00p

Previous CloseN/A

Volume750.00

Average Volume (3M)10.86K

Market Cap

£220.86M

Enterprise Value269.30M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.89

Next Earnings

Aug 27, 2025

EPS Estimate

-0.86

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding111,954,600

10 Day Avg. Volume10,068

30 Day Avg. Volume10,855

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£685.66

Price Target Upside230.44% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Efficacy And SafetyBexmarilimab delivers an improved complete remission rate, strengthening confidence in its longer-term benefits and reducing risks for the upcoming registrational program.

Market PositioningThe potential positioning of Bexmarilimab across both frontline and relapsed/refractory MDS settings makes it a uniquely attractive asset.

Regulatory ProgressRegulatory progress further strengthens the case for Bex in MDS, with the FDA granting Fast Track Designation and providing positive feedback on the registrational strategy, potentially expediting the approval timeline.

Bears Say

Clinical Development RisksThere are risks related to clinical development, competition, the novel Clever-1 mechanism, commercialization, reimbursement, pricing, business development, and capital markets.

CompetitionRisks include clinical development risk tied to programs, particularly Bex, in multiple tumor types, and competitor risk in alternative or similar immunotherapies in oncology.

Program Development RisksRisks include clinical development risk tied to programs, particularly Bex, in multiple tumor types, among other factors.

Faron Pharmaceuticals Oy News

Faron Pharmaceuticals Approves Share Subscription for Bond Amortisation

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has provided an update. Faron Pharmaceuticals Ltd has approved the exercise of...

1d ago

Buy Rating Affirmed for Faron Pharmaceuticals Oy: Promising Bexmarilimab Trial Results and Strategic Advancements

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Faron Pharmaceuticals Oy and keeping the price...

2d ago

Faron Pharmaceuticals Achieves 43% Remission Rate in BEXMAB Trial

Faron Pharmaceuticals Oy ( ($GB:FARN) ) just unveiled an announcement. Faron Pharmaceuticals announced a significant increase in the...

2d ago

Faron Pharmaceuticals Achieves 43% Remission Rate in HR-MDS Trial

The latest announcement is out from Faron Pharmaceuticals Oy ( ($GB:FARN) ). Faron Pharmaceuticals announced a significant increase...

2d ago

Faron Pharmaceuticals Chairman Increases Shareholding

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has issued an announcement. Faron Pharmaceuticals announced that its Non-Executive Chairman, Tuomo...

1M ago

Faron Pharmaceuticals Oy’s Bexmarilimab: A Promising Buy with Transformative Potential in MDS Treatment

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Faron Pharmaceuticals Oy (FARN – Research Report) today...

1M ago

Faron Pharmaceuticals CEO Increases Stake in Company

The latest announcement is out from Faron Pharmaceuticals Oy ( ($GB:FARN) ). Faron Pharmaceuticals Ltd announced that its...

1M ago

Faron Pharmaceuticals Founders Donate and Sell Shares to Support Medical Research

The latest announcement is out from Faron Pharmaceuticals Oy ( ($GB:FARN) ). Faron Pharmaceuticals Ltd announced that its...

2M ago

Promising Phase 2 Results and Regulatory Progress Drive Buy Rating for Faron Pharmaceuticals’ Bexmarilimab

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Faron Pharmaceuticals Oy (FARN – Research Report) today...

2M ago

Faron Pharmaceuticals Registers Over 5 Million New Shares to Bolster Market Position

Faron Pharmaceuticals Oy ( ($GB:FARN) ) has shared an update. Faron Pharmaceuticals Ltd has registered 5,352,989 new shares,...

2M ago

FARN FAQ

What was Faron Pharmaceuticals Oy’s price range in the past 12 months?

Faron Pharmaceuticals Oy lowest share price was 140.00p and its highest was 270.00p in the past 12 months.

What is Faron Pharmaceuticals Oy’s market cap?

Faron Pharmaceuticals Oy’s market cap is £220.86M.

When is Faron Pharmaceuticals Oy’s upcoming earnings report date?

Faron Pharmaceuticals Oy’s upcoming earnings report date is Aug 27, 2025 which is in 19 days.

How were Faron Pharmaceuticals Oy’s earnings last quarter?

Faron Pharmaceuticals Oy released its earnings results on Feb 27, 2025. The company reported 0p earnings per share for the quarter, beating the consensus estimate of -0.139p by 0.139p.

Is Faron Pharmaceuticals Oy overvalued?

According to Wall Street analysts Faron Pharmaceuticals Oy’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Faron Pharmaceuticals Oy pay dividends?

Faron Pharmaceuticals Oy does not currently pay dividends.

What is Faron Pharmaceuticals Oy’s EPS estimate?

Faron Pharmaceuticals Oy’s EPS estimate is -0.86.

How many shares outstanding does Faron Pharmaceuticals Oy have?

Faron Pharmaceuticals Oy has 111,954,600 shares outstanding.

What happened to Faron Pharmaceuticals Oy’s price movement after its last earnings report?

Faron Pharmaceuticals Oy reported an EPS of 0p in its last earnings report, beating expectations of -0.139p. Following the earnings report the stock price went up 1.471%.

Which hedge fund is a major shareholder of Faron Pharmaceuticals Oy?

Currently, no hedge funds are holding shares in GB:FARN

Company Description

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Faron Pharmaceuticals Oy (FARN) Earnings & Revenues

Historic Earnings Reports

FARN Stock 12 Month Forecast

Average Price Target

685.66p

▲(230.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"161":"161p","371":"371p","581":"581p","791":"791p","1001":"1,001p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">1.00K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":685.66,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">685.66p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":371.31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">371.31p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[161,371,581,791,1001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,192.5,254.6153846153846,316.7307692307692,378.8461538461538,440.96153846153845,503.0769230769231,565.1923076923076,627.3076923076923,689.4230769230769,751.5384615384615,813.6538461538462,875.7692307692307,937.8846153846154,{"y":1000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,192.5,230.4353846153846,268.3707692307692,306.30615384615385,344.2415384615384,382.17692307692306,420.1123076923077,458.0476923076923,495.9830769230769,533.9184615384615,571.8538461538461,609.7892307692307,647.7246153846154,{"y":685.66,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,192.5,206.2546153846154,220.00923076923078,233.76384615384615,247.51846153846154,261.2730769230769,275.0276923076923,288.78230769230765,302.5369230769231,316.2915384615385,330.04615384615386,343.8007692307692,357.5553846153846,{"y":371.31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":162.5,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":215,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":165,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.5,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":170,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":209,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":192.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":202.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >